Ocular TherapeutixTM Reports on Topline Results of Phase 2b Glaucoma Clinical Trial
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results through 90 days of therapy from its Phase 2b clinical trial of OTX-TP (sustained release travoprost) for the treatment of glaucoma and ocular hypertension. In this trial, the duration of effect as measured by the clinically meaningful reduction of intra
